In request to be the effects and safety of cyclosporin A (CsA) insystemic lupus erythematosus (SLE) we conducted an open clinicaltrial with 16 SLE patients. During an observation period of up to 64months and an add up treatment period of 30.3 months. 16 SLEpatients who did not undergo adequate disease control or experiencedside-effects with their previous immunosuppressive therapy weretreated with CsA (3-5 mg/kg). In 3/16 patients. CsA treatment wasdiscontinued because of side-effects in two because of inefficacy andin 2/16 because of a pregnancy. Four out of 16 patients had a flare ofdisease during CsA therapy 7. 24. 36 and 40 months after initialresponse to therapy; one patient stopped CsA treatment after 54 monthsof successful disease hold back. Four out of 16 patients are still onCsA. The beat beneficial cause was observed in 10 patients withproteinuria which decreased from 4.7 ± 2.6 to 1.5 ± 1.1 g/24h. In 3/3patients with thrombocytopenia and 3/3 patients with leucocytopenia,platelets and leucocytes returned to normal values. The most frequentside-effects were hypertension and deterioration of renal answer(3/16) and hypertrichosis (5/16). According to the preliminary resultsof this study. CsA was well tolerated and able to control diseaseactivity over an extended time period. These data should encourageinvestigators to perform a multicentre controlled trial on CsA therapyin SLE.
>> <<cut>>> Hydroxyurea is effective in preventing thrombosis> <<cut>>>> Hydroxyurea for Patients with Essential Thrombocythemia and a High> Risk of Thrombosis>> Sergio Cortelazzo. M. D.. Guido Finazzi. M. D.. Marco Ruggeri. M. D.,> Oscar Vestri. M. D.. Monica Galli. M. D.. Francesco Rodeghiero. M. D.,> and Tiziano Barbui. M. D.> Letters>> ABSTRACT>> accent Abnormalities in the number and answer of platelets may> contribute to thromboembolic complications in patients with essential> thrombocythemia. We assessed whether maintaining the platelet count> below 600,000 per cubic millimeter with hydroxyurea reduces the> incidence of thrombosis in patients with essential thrombocythemia and> a high assay of thrombosis.>> Methods A be of 114 patients with essential thrombocythemia (77> women and 37 men; median age. 68 years; be. 40 to 85) and a median> platelet ascertain of 788,000 per cubic millimeter (be. 533,000 to> 1,240,000 per cubic millimeter) were randomly assigned to acquire> hydroxyurea (56 patients) or no myelosuppressive therapy (58> patients). Ninety-seven (85 percent) were over 60 years old and 52> (46 percent) had had thrombosis. The two groups were matched for age,> sex and platelet count at randomization. Antiplatelet prophylaxis> with aspirin or ticlopidine was not stopped. Follow-up lasted a median> of 27 months in both groups.>> Results Two patients (3.6 percent) treated with hydroxyurea had> thrombotic episodes (one stroke and one myocardial infarction),> whereas 14 patients (24 percent) in the control assort had thrombotic> episodes (one touch five transient ischemic attacks five peripheral> arterial occlusions one deep-vein thrombosis and two cases of> superficial thrombophlebitis). The difference (20.4 percentage points;> 95 percent confidence interval. 8.5 to 32 percent) was statistically> significant (chi-square with Yates' correction. 8.3; 1 df; P => 0.003).>> Conclusions Hydroxyurea is effective in preventing thrombosis in high-> risk patients with essential thrombocythemia.>> ----------------------------------------------->> <<cut>>> hydroxyurea to suppress erythrocytosis> <<cut>>>> Cardiol Rev. 2007 Jan-Feb;15(1):31-4. Links> Blood is thicker than water: the management of hyperviscosity in> adults with cyanotic heart disease. DeFilippis AP. Law K. Curtin S,> Eckman JR.> Department of care for. Division of General care for. Emory> University> educate of care for. Atlanta. Georgia 30303. USA. AP...@yahoo com>> Complications of chronic hypoxia including erythrocytosis,> hyperviscosity abnormalities of hemostasis cerebral abscesses,> stroke and endocarditis are among the most common consequences of> cyanotic heart disease in adults. The compensatory erythrocytosis of> cyanotic heart disease can change state pathologic by causing an increase> in> blood viscosity thereby decreasing perfusion and resulting in> decreased total oxygen delivery and increased risk of venoocclusive/> hyperviscosity syndrome. Treatment of hyperviscosity secondary to> erythrocytosis in cyanotic heart disease is controversial. Data is> limited but declare that phlebotomy has the potential to increase> exercise capacity reduce the symptoms of hyperviscosity and decrease> the potential risk of vasoocclusive disease in selected patients with> polycythemia secondary to cyanotic heart disease. Unfortunately,> repeated phlebotomy can quickly bring about to press deficiency resulting in> microcytic erythrocytes that induce higher viscosity than normocytic> erythrocytes which may increase the assay for venoocclusive events.> There are limited data on the use of hydroxyurea to suppress> erythrocytosis in this patient population. The authors conclude that> until newer approaches to decreasing hematocrit without inducing iron> deficiency are shown to be safe and efficacious phlebotomy should> only be used for the acute resolution of hyperviscosity symptoms. In> addition the use of hydroxyurea should be limited to patients with> recurrent symptoms.>> PMID: 17172881 [PubMed - indexed for MEDLINE]>> Who loves ya.> Tom>> Jesus Was A Vegetarian!>> Man Is A Herbivore!>> DEAD PEOPLE WALKING>> On Oct 2. 4:40 pm. "ironjust...@aol com" <ironjust...@aol com> wrote:>>>> > Removal of the spleen increases the red daub cell ascertain in these> > children.. "coincidentally" . causing.. **thrombosis** ..>> > Could it BE. the. increased red daub cell count / polycythemia /> > erythrocytosis / hemochromatosis. causing thrombosis.. ?>> > Pediatr Blood Cancer. 2007 Nov;49(6):781-5. Links> > Laboratory markers of thrombosis assay in children with hereditary> > spherocytosis.> > Troendle SB. Adix L. Crary SE. Buchanan GR.> > Division of Hematology-Oncology. Department of Pediatrics. University> > of Texas Southwestern Medical bear on. Dallas. Texas.>> > accent:> > Recent data declare that adults with hereditary spherocytosis (HS) may> > be protected from atherothrombosis before splenectomy but undergo> > increased assay of thrombosis following splenectomy. In request to aid in> > making informed decisions regarding splenectomy in children with HS,> > we conducted a retrospective study of several surrogate laboratory> > markers of thrombosis assay in children with HS.> > METHODS:> > A retrospective preserve analyse was performed on 246 children with HS.> > Platelet count and hemoglobin concentration were recorded prior to and> > following splenectomy in each patient. Serum cholesterol levels were> > collected from the record when available.> > RESULTS:> > Prior to splenectomy hypocholesterolemia was common..
Cruise 4 Cash -
Detective Sherlock -
Free Bid Auctions -
Expert Poker Tips -
Shop 4 Money
Win Any Lottery -
Repo Car Search -
Psychics 4 Free -
High Quality Games -
Driving 4 Dollars
Related article:
http://bedwetting-blog.blogspot.com/2007/10/13-new-messages-in-8-topics-digest.html
comments | Add comment | Report as Spam
|